



## ASX Announcement

10 October 2024

# Cambium Bio Strengthens Leadership with Two Key Appointments

**Sydney, Australia; 10 October 2024:** Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce two key appointments to strengthen its scientific and leadership teams.

### Appointment of Dr. Louis Tong to Scientific Advisory Board

Dr. Louis Tong, a distinguished expert in ocular immunology and dry eye disease, has been appointed to Cambium Bio's Scientific Advisory Board. Dr. Tong is a Senior Consultant at the Singapore National Eye Centre, specializing in Corneal & External Eye Disease, and an Adjunct Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore. He is an internationally renowned clinician-scientist with over two decades of experience in ophthalmology, particularly in the areas of dry eye research and treatment development. He has authored more than 150 peer-reviewed publications and holds several patents in ophthalmic therapies. His wealth of expertise in clinical research will be instrumental in guiding Cambium Bio's ongoing development of novel dry eye disease therapeutics.

### Appointment of Dr. ChiTai Chang to Board of Directors

Dr. ChiTai Chang has been appointed to Cambium Bio's Board of Directors as a representative of Orient EuroPharma (Cyntec Co., Ltd.). Dr. Chang brings extensive experience in the pharmaceutical industry, with a strong background in strategic business development, commercialization of innovative products, and building partnerships in the healthcare sector. He has held senior leadership roles at multiple biotechnology firms where he successfully oversaw several drug development programs from early-stage research to regulatory approvals. Dr. Chang is currently the Chief Strategy Officer at Orient EuroPharma and holds a PhD in Chemistry from the University of Pittsburgh. Dr. Chang's proven track record in steering clinical programs to successful market entry will be invaluable as Cambium Bio progresses towards its goal of achieving FDA BLA approval for its lead candidate, Elate Ocular<sup>®</sup>, in dry eye disease.

## CEO's Commentary

Cambium Bio CEO, **Karolis Rosickas**, commented: "We are thrilled to welcome Dr. Louis Tong and Dr. ChiTai Chang to Cambium Bio at this pivotal stage in our company's growth. Dr. Tong's deep knowledge of dry eye disease and Dr. Chang's strategic leadership experience in drug development will play crucial roles in our efforts to advance our clinical pipeline and bring Elate Ocular® to market."

These appointments reflect Cambium Bio's ongoing commitment to enhancing its leadership capabilities and scientific acumen, ensuring the company remains at the forefront of ophthalmic innovation.

### About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit [www.cambium.bio](http://www.cambium.bio)

- ENDS -

### Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung  
Corporate Secretary  
[info@cambium.bio](mailto:info@cambium.bio)  
1 300 995 098